Literature DB >> 30756471

Circulating miR-29b positively correlates with non-alcoholic fatty liver disease in a Chinese population.

Zhen He1, Jian Jun Yang2, Rong Zhang1, Hua Ting Li1, Liang Wu1, Feng Jiang1, Wei Ping Jia1, Cheng Hu1,3.   

Abstract

OBJECTIVE: Early screening of non-alcoholic fatty liver disease (NAFLD) is of great significance for the early detection and intervention in NAFLD. MicroRNAs (miRNAs) are important regulators of metabolic diseases including NAFLD. The aim of this study was to investigate the association of serum miR-29a-c with NAFLD in a Chinese population.
METHODS: Participants were divided into four groups based on the presence or absence of NAFLD and/or type 2 diabetes mellitus (T2DM). Quantitative polymerase chain reaction analysis was performed to quantify serum level of miR-29a-c. The association of miR-29a-c with NAFLD was evaluated.
RESULTS: Serum miR-29b, but not miR-29a or miR-29c, was positively associated with NAFLD (odds ratio [OR] 2.04 [1.16- 3.58], P = 0.013). Additionally, age, serum triglyceride and fasting plasma glucose (FPG) levels were independently associated with miR-29b (β ± standard error [SE] = 0.004 ± 0.002, P = 0.019 for age; β ± SE = 0.110 ± 0.054, P = 0.042 for triglyceride; and β ± SE = 0.389 ± 0.161, P = 0.016 for FPG). MiR-29b level was positively correlated with intrahepatic lipid content (β ± SE = 6.055 ± 2.630, P = 0.024) after adjusted for age, sex, and body mass index.
CONCLUSIONS: Serum miR-29b was associated with intrahepatic lipid content and NAFLD in a Chinese population-based study.
© 2019 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  circulating microRNA; diabetes mellitus; miR-29a, miR-29b, miR-29c, non-alcoholic fatty liver disease

Mesh:

Substances:

Year:  2019        PMID: 30756471     DOI: 10.1111/1751-2980.12716

Source DB:  PubMed          Journal:  J Dig Dis        ISSN: 1751-2972            Impact factor:   2.325


  5 in total

1.  Circulating microRNA‑135a‑3p in serum extracellular vesicles as a potential biological marker of non‑alcoholic fatty liver disease.

Authors:  Hemin Jiang; Yu Qian; Ziyang Shen; Yuwei Liu; Yunqiang He; Rui Gao; Min Shen; Shu Chen; Qi Fu; Tao Yang
Journal:  Mol Med Rep       Date:  2021-05-06       Impact factor: 2.952

2.  Transplantation of brown adipose tissue up-regulates miR-99a to ameliorate liver metabolic disorders in diabetic mice by targeting NOX4.

Authors:  Ping Li; Cunxia Fan; Yingying Cai; Shu Fang; Yanmei Zeng; Yudan Zhang; Xiaochun Lin; Hongbin Zhang; Yaoming Xue; Meiping Guan
Journal:  Adipocyte       Date:  2020-12       Impact factor: 4.534

Review 3.  Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD.

Authors:  Stefania Di Mauro; Alessandra Scamporrino; Agnese Filippello; Antonino Di Pino; Roberto Scicali; Roberta Malaguarnera; Francesco Purrello; Salvatore Piro
Journal:  Int J Mol Sci       Date:  2021-11-02       Impact factor: 5.923

Review 4.  Noncoding RNAs in doxorubicin-induced cardiotoxicity and their potential as biomarkers and therapeutic targets.

Authors:  Hong-Ge Fa; Wen-Guang Chang; Xue-Juan Zhang; Dan-Dan Xiao; Jian-Xun Wang
Journal:  Acta Pharmacol Sin       Date:  2020-07-21       Impact factor: 6.150

5.  Deciphering the role of epigenetic modifications in fatty liver disease: A systematic review.

Authors:  Xiaofang Zhang; Eralda Asllanaj; Masoud Amiri; Eliana Portilla-Fernandez; Wichor M Bramer; Jana Nano; Trudy Voortman; Qiuwei Pan; Mohsen Ghanbari
Journal:  Eur J Clin Invest       Date:  2021-01-04       Impact factor: 4.686

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.